Journal
CANCER CELL
Volume 19, Issue 4, Pages 527-540Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2011.02.017
Keywords
-
Categories
Funding
- Children's Tumor Foundation
- FP7 EUCAAD project [200755]
- Swedish Cancer Society
- Swedish Research Council
- Cancer Society in Stockholm
- Vinnova and Karolinska Institutet
- [CA124495]
Ask authors/readers for more resources
The Merlin/NF2 tumor suppressor restrains cell growth and tumorigenesis by controlling contact-dependent inhibition of proliferation. We have identified a tight-junction-associated protein complex comprising Merlin, Angiomotin, Patj, and Pals1. We demonstrate that Angiomotin functions downstream of Merlin and upstream of Rich1, a small GTPase Activating Protein, as a positive regulator of Rac1. Merlin, through competitive binding to Angiomotin, releases Rich1 from the Angiomotin-inhibitory complex, allowing Rich1 to inactivate Rac1, ultimately leading to attenuation of Rac1 and Ras-MAPK pathways. Patient-derived Merlin mutants show diminished binding capacities to Angiomotin and are unable to dissociate Rich1 from Angiomotin or inhibit MAPK signaling. Depletion of Angiomotin in Nf2(-/-) Schwann cells attenuates the Ras-MAPK signaling pathway, impedes cellular proliferation in vitro and tumorigenesis in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available